Forskolin

Catalog No.S2449 Synonyms: Coleonol

Forskolin Chemical Structure

Molecular Weight(MW): 410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 270 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 42 Publications

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Description Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
Targets
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
In vitro

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NWrzPIZUTnWwY4Tpc44hSXO|YYm= NX3LdpRCOTBizszN M1jpclYhcA>? NIDCPJZqdmO{ZXHz[ZMheGixc4Doc5J6dGG2aX;uJI9nKG:4ZYLlfJBz\XO|ZXSgT2xJVDNiYYSgV|Q{Ow>? MoniNlY1OzV2OUi=
Mo-DCs MnHxSpVv[3Srb36gRZN{[Xl? MXy1NEDPxE1? NYm5NVNYOjUkgJno M3yzS5Bzd22xdHXzJGlNNTJ|IIDyc4R2[3Srb36gbY4hfGinIIP1dIVzdmG2YX70JI9nKHq7bX;zZY4he3SrbYXsZZRm\CCPbz3ER5PDqA>? NVr2bIhOOjZ2MUK5OFg>
RBMECs  NHzOXIFHfW6ldHnvckBCe3OjeR?= MXu1xsDPxE1? NHfnWlYyyqCq MVTicI9kc3NidHjlJHJi[zFiaX7hZ5RqfmG2aX;uJIlv\HWlZXSgZpkhTU2DUD3JTS=> M2LpVlI3OzV6MEO5
INA-6 M3\WT2NmdGxiVnnhZoltcXS7IFHzd4F6 NU\ZTYFQOC1zMECg{txO NGX4VoE4OuLCiXi= NFTB[2VqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> M{P6ZlI3OzB4NkK0
OPM-2 M3XCemNmdGxiVnnhZoltcXS7IFHzd4F6 NXvxbZl1OC1zMECg{txO NX3JbYxUPzMkgJno NHvNNHlqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NVH1e3NCOjZ|ME[2NlQ>
U266 Mk\qR4VtdCCYaXHibYxqfHliQYPzZZk> NXTJRlE{OC1zMECg{txO NITwbVM4OuLCiXi= MXvpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MWGyOlMxPjZ{NB?=
H929 MkjhR4VtdCCYaXHibYxqfHliQYPzZZk> NELyUG0xNTFyMDFOwG0> MX[3NwKBkWh? NWHDd3VmcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> NHTlRZUzPjNyNk[yOC=>
RPMI 8226 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHfzdpExNTFyMDFOwG0> Mm\TO|LjiImq M3uzZYlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 MkezNlY{ODZ4MkS=
MDCK  NFv2OolHfW6ldHnvckBCe3OjeR?= NH;XXGMyOCEEtV2= M1[zUVI1KGh? MoLjSG1UVw>? MmXjeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhXEeILd8yNUBidmRiQ2THSuKh NGHIRmEzPjJyMkO1Ni=>
MDCK  Mlm5SpVv[3Srb36gRZN{[Xl? M2rJXVExKML3TR?= MmX6NlQhcA>? M4LsXGROW09? M4S0WolvcGmkaYTzJJRp\SCrbnPy[YF{\WRiZYjwdoV{e2mxbjDv[kBHViClYYXz[YQh[nliVFfGMe6zOQ>? NYTE[Y52OjZ{MEKzOVI>
Spinal cords  MkDFSpVv[3Srb36gRZN{[Xl? MXWxxsDPxE1? MWCzNEBucW5? MnfXd5RqdXWuYYTld{BkSU2SIHzleoVtew>? M{jUNVI3OTJ4OUK2
BeWo  MXXGeY5kfGmxbjDBd5NigQ>? Mmn2NlXjiIoQvF2= Mk\rNlQwPDhxN{KgbC=> NH72fVRt\WGmczD0c{BidiCrbnPy[YF{\SCrbjD0bIUh\XiycnXzd4lwdiCxZjDveIhmeiCodYPpc44hdWG{a3Xydy=> MkLCNlYxPTN3NEm=
bovine oocytes MlvQSpVv[3Srb36gRZN{[Xl? M{LJSFExOMLizszN NGTpe20yOsLiaB?= M1PUWolvcGmkaYTzJJRp\SCnZn\lZ5Qhd2ZiTmDQRUBidmRxb4KgUnBRSyC2bzDzeIlufWyjdHWgdoV{fW2ydHnvckBw\iCvZXnvd4l{ MVeyOlA2OTZzMR?=
Caco-2  MWPGeY5kfGmxbjDBd5NigQ>? MUiwMlEwOS9zMDFOwG0> MY[yNOKhdWmw NITzNnRqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hcW62cnHj[YxtfWyjcjDjRW1RKGyndnXsdy=> MlH5NlYxPDlzMEK=
Caco-2  MorlSpVv[3Srb36gRZN{[Xl? M{PoT|AvOS9zL{GwJO69VQ>? MmfCNlQhcA>? MVrpcoNz\WG|ZYOgUXJROiCycn;0[YlvKGyndnXs NGPZSIUzPjB2OUGwNi=>
AML-12  MWrGeY5kfGmxbjDBd5NigQ>? MnnCNlAh|ryP NH;GNZM{KGh? NYjkVWZNfXC{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNiYYSgWIhzNTRzMTDhcoQhW2W{LUS5Ny=> NF3iPVkzPjB2OEm4OS=>
AML-12  MnPtSpVv[3Srb36gRZN{[Xl? MmLQNlAh|ryP NIrnNZAyNThiaB?= M164UIlv[3KnYYPld{BodHWlb4PlJJBzd2S3Y4Tpc44> NYn5TVQyOjZyNEi5PFU>
AML-12  NVjTUmRCTnWwY4Tpc44hSXO|YYm= MVOyNEDPxE1? NG\jeHc{KGh? NGDoN3p2eC2{ZXf1cIF1\XQEoGDnZ|FiNMLiUHXwZ4stKGGwZNMgS|Zx[8LibWLORUBt\X[nbIO= MoHqNlYxPDh7OEW=
AML-12  M13GW2Z2dmO2aX;uJGF{e2G7 MlrSNlAh|ryP MlfxN{Bp M1nQSYlv\HWlZYOgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKG:oIFPSWGMzyqB? NIC2cpYzPjB2OEm4OS=>
RBMECs NFKyeGhHfW6ldHnvckBCe3OjeR?= M{GxdVXDqM7:TR?= M3fJeFEhcA>? M2XIO4lvcGmkaYTzJGVOSVBvSVmtbY5lfWOnZDDpcoFkfGm4YYTpc44hd2ZiUnHwNeKh Ml3aNlYxPDR4NkO=
EndoC-βH1 M17IPWZ2dmO2aX;uJGF{e2G7 M1;VeVXDqM7:TR?= NU\VTGFOOSCq MlfDdI91\W62aXH0[ZMh\2y3Y3;z[U1qdmS3Y3XkJIlve3WuaX6gd4VkemW2aX;uJIlvKHSqZTDwdoV{\W6lZTDv[kBodHWlb4Pl NXnpcotqOjZyMki1OlI>
EndoC-βH1 Mm\rSpVv[3Srb36gRZN{[Xl? MmD2OeKh|ryP Mn6zNUBp MlzWcIVi\HNidH:gZUB{fHKxbnegZ2FOWCCrbnPy[YF{\Q>? Mke0NlYxOjh3NkK=
SH-SY5Y NV\jeWVFTnWwY4Tpc44hSXO|YYm= NFfnSoU{OCEQvF2= NHPxPGE{OCCvaX6= MYTEUXNQ NUSyOGk{e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKGGldHn2ZZRqd25ib3[gVGtC NWfjemJbOjZyMkWxN|c>
PC-3 MVvGeY5kfGmxbjDBd5NigQ>? MlPFOFAhyrWP NV\tVoZnOiCq NUW1bFlxTE2VTx?= MlLHcIVi\HNidH:gVHAzSSCjY4TpeoF1cW:w NVex[JNQOjZyMkO4N|Y>
PC-3 NIXJXnlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnPiOFAhyrWP NI\qS2gzPC92OD:3NkBp M1HpW2ROW09? Mniw[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? NV;LTo03OjZyMkO4N|Y>
SCG MlP1SpVv[3Srb36gRZN{[Xl? MViyNEDPxE4EoB?= NH7aUGFFVVOR MoTndoV3\XK|aXLsfUB{fXCycnXzd4V{KEmNVjD3bZRpKGFiSVO1NEBw\iB{ND60JO69VQ>? NVjad5dIOjV7NkKxN|I>
HEK-293 NXjZZY9OTnWwY4Tpc44hSXO|YYm= NYjicIJrOzVizszNxsA> NUDwOnE4TE2VTx?= M37WVYlv\HWlZYOgZUBkd26|cHnjeY92eyEkgKzpcoFkfGm4YYTpc47jiJ1ib3[geIhmKEu4Mj6xJIN2enKnboS= NEjHeVUzPTl4MkGzNi=>
SCG MoDhSpVv[3Srb36gRZN{[Xl? NF[0fVIyODBizszNxsA> MkHBSG1UVw>? NWPYUoRMemWmdXPld{B1cGViZYjjbZRi[mmuaYT5JI9nKFOFRzDu[ZVzd26| MmHENlU6PjJzM{K=
PCCL3 NVK5OmVyTnWwY4Tpc44hSXO|YYm= NU\1[lNKOTBiwsXN MYGyOEBp NGK5O5JmdmijbnPld{BFfU:6MjDwdo9ud3SncjD0doFve2O{aYD0bY9vKGGldHn2bZR6yqEkgJu= NELhNYQzPTl4MEm1Oi=>
3T3-L1 preadipocytes NGHK[mFHfW6ldHnvckBCe3OjeR?= NYn3S5JLOTBizszNxsA> NYi1bWk1OTJiaB?= NV\O[ZN1cW6mdXPld{BEWkWEIIDoc5NxcG:{eXzheIlwdiCjbnSgR{9GSlEQsjDlfJBz\XO|aX;u MXWyOVkzQDB3OB?=
H295R  NWT0SpR2TnWwY4Tpc44hSXO|YYm= M3rFVFExyqEQvF2= NE\JOI81QMLiaB?= MYPpcoNz\WG|ZYOgd5Rmem:rZDDt[ZRi[m:uaYTld{BqdiC2aHWgZY5lem:pZX6sJI1qdmW{YXzvMUBidmRiZ3z1Z49kd3K2aXPvbYQheGG2aIfhfZM> NYrYcJBWOjV6Nkm1OVY>
PBMC NXO0[VZOTnWwY4Tpc44hSXO|YYm= M1mxclUxyqEQvF2= MV[yOOKhcMLi MoX0bY5pcWKrdIOgeIhmKGmwY4LlZZNm\CC|ZXPy[ZRqd25ib3[gWG5HKGmwZIXj[YQh[nlidHjlJGRRTQ>? NH;aXokzPTh4NkC3PS=>
GLUTag  NFvDRZhHfW6ldHnvckBCe3OjeR?= NVfF[JRCOTEkgJpCuW0> M2f5U|AwOi92IHi= M1:xbpN1cW23bHH0[ZMhT0ySLUGgd4VkemW2aX;uJINwfHKnYYTl[EB4cXSqIFnCUXg> M2TFfFI2QDN{NkOx
GLUTag  NUWzbFc4TnWwY4Tpc44hSXO|YYm= NVn2[4Q5OTEkgJpCuW0> MV[0JIg> MWPpcoNz\WG|ZYOgeIhmKHCFUlXCJIxmfmWuczD3bZRpKHSqZTDJRm1Z M3iw[lI2QDN{NkOx
BAECs Mn3hSpVv[3Srb36gRZN{[Xl? NGXnUpYzPSEQvF2= M4HISVI1KGh? M3PCXYVvcGGwY3XzJJRp\SCjY4TpeoF1cW:wIH;mJHBRSVMQsTDifUA2KM7:TTDy[ZN3\XKjdILvcEwhXDSKUzygc5IhPC2SQWC= NH3Hd2IzPTd7OEiyOi=>
PC12 Mmi3SpVv[3Srb36gRZN{[Xl? NWTY[nFpOjYEoN88US=> M2PXWFQ5KGh? NX;hfIx7[WO2aY\heIV{KGODTWC= Mn2xNlU4Pjl|MEW=
GH3 M{O0V2Z2dmO2aX;uJGF{e2G7 NEmyPJQyyqEQvF2= MVK2MYg> Mn;NZZR1\W63YYTld{B1cGViY3;ydoVt[XSrb36gZoV1f2WnbjDQVmwh[W6mIFLtZYwyKGW6cILld5Nqd25? NELlVnMzPTd{N{CxPC=>
GH3 NHLUbpdHfW6ldHnvckBCe3OjeR?= MnnPNeKh|ryP MYW2MYg> MXzpcoR2[2W|IGDSUEBidmRiQn3hcFEtKGK3dDDuc5QhS2yxY3usJI1TVkFiZYjwdoV{e2mxbh?= NYH0TotoOjV5MkewNVg>
BeWo MlH2SpVv[3Srb36gRZN{[Xl? NF36SWMyOOLCit88UeKh NIX1NWw4OiCq MXjEUXNQ NFfRc4tu\WSrYYTld{BD\VexIHPlcIwh\GmoZnXy[Y51cWG2aX;u M3S3SlI2PzF|NEK1
oocytes NGO5bI5HfW6ldHnvckBCe3OjeR?= NEDKXFM2KM7:TR?= NHrSbW4zPCCq NF3ZN4JifHSnboXheIV{KHKqLXnud5VtcW5iYXP0bY9vKG:wIH;vZ5l1\SCJVlLEJJNq\26rZnnjZY51dHoEoB?= NYf4T2gzOjV5MEe4OVQ>
SC M4fxcGZ2dmO2aX;uJGF{e2G7 NEjtNYExNjVizszN Mn7JNlQhcA>? NUnVPYlxdWmvaXPrd{B1cGViZX\m[YN1KG:oIHPBUXAh[W6jbH;nd{BwdiCRMTDhcoQhVUKSIHX4dJJme3Orb36= M4WzVVI2PzB3OEe0
SC MmjoSpVv[3Srb36gRZN{[Xl? NGTjWXUxNjVizszN MlL3O|IhcA>? NUDIblRDcW6lcnXhd4V{KGKxdHigT5JwgC1{MDDhcoQhVzFiZYjwdoV{e2mxbjDpckBigG:wLYLlcIF1\WRiU1PzJIJ2fCCxbnz5JGtzd3hvMkFCpC=> NHrzOHEzPTdyNUi3OC=>
UACC-647  NFfrT4dHfW6ldHnvckBCe3OjeR?= NG[2d4ZFVVOR NWDDfWR[dGWjZIOgeI8h[SC{aYPlJIlvKGODTWCgcIV3\Wy|IDjFR|UxyqB;wrCyNE4{QcLizszNLS=> MWeyOVcxOzB{NR?=
UACC-647  MVLGeY5kfGmxbjDBd5NigQ>? NUi2cnljOTEEoN88US=> NUL5R3BnOTVibXnu NFHvSJdFVVOR MYrpcohq[mm2czDFVmsheGixc4Doc5J6dGG2aX;u M{HITlI2PzB|MEK1
UACC-647  NYWyeIhNTnWwY4Tpc44hSXO|YYm= MWSxNOKh|ryP MVqxOUBucW5? NUHlW|JJTE2VTx?= NXTB[oZ2cW6lcnXhd4V{KGWHRkKgdIhwe3Cqb4L5cIF1cW:wIHzleoVte8Li M1nub|I2PzB|MEK1
SH-SY5Y  NH:4R21HfW6ldHnvckBCe3OjeR?= NUK5fpFZOTEEoN88US=> MnLXNeKhcMLi NFT0RVhqdmO{ZXHz[ZMhVFWFIHHjeIl3cXS7 Mnz4NlU2QTd2M{O=
SH-SY5Y  MoSySpVv[3Srb36gRZN{[Xl? NIXyb20yOMLizszN MVOxxsBpyqB? NIn2dWtqdmO{ZXHz[ZMhSUeFMTDtVm5CKGyndnXs MorSNlU2QTd2M{O=
hADSCs MYHGeY5kfGmxbjDBd5NigQ>? M3P6SFXjiIoEtV2= NYXUOpp[OzBibXnu MYnpcoNz\WG|ZYOgZ2FOWCCuZY\lcJM> MXyyOVU6OTlyOB?=
HEK293  M4fkeWZ2dmO2aX;uJGF{e2G7 MUW15qCKyrWP M33NPVMxKG2rbh?= MW\pcoNz\WG|ZYOgZ2FOWCCuZY\lcJM> NIHzd|YzPTV7MUmwPC=>
3T3-L1 NH;wbolHfW6ldHnvckBCe3OjeR?= NIrp[YQzNjVxNTFOwG0> MUGyOEBpyqB? NIS0O2R{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDBWGdNKHC{b4TlbY4h\XiycnXzd4lwdiCjdDDhcIwh\G:|ZYOgeIV{fGWm NHLPZpUzPTV7MEW5Oy=>
OCI-Ly1  NHrYeWNHfW6ldHnvckBCe3OjeR?= MV20NOKh|ryP Ml7yNeKhcMLi Ml;ESG1UVw>? Mn7GbY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= NGDmZoszPTV5NkKyNC=>
OCI-Ly18  MkjXSpVv[3Srb36gRZN{[Xl? M2joXVQxyqEQvF2= NEKyenoyyqCqwrC= NUnCTHp1TE2VTx?= MkTybY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= M{K5R|I2PTd4MkKw
BeWo Mnj0SpVv[3Srb36gRZN{[Xl? NXPvRYZ4OjEEoNM1US=> NXH0VmpXPDkEoHi= MXHEUXNQ NYLMVYhlcW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> MkLnNlU2PjZ5NEC=
BeWo NETUd21HfW6ldHnvckBCe3OjeR?= NGXqRoUzOMLiwsXN NX2yUmdxPDkEoHi= NIXISlBFVVOR NXnLSHhPcW6lcnXhd4V{KHSqZTDh[Ihme2mxbjDv[kBVUFBvMTDtc45w[3m2ZYO= NUnvdlFqOjV3Nk[3OFA>
LNCaP  Mn7sSpVv[3Srb36gRZN{[Xl? NIrSRlYyOMLizszN MmK0NVIhcMLi NFX0OHNFVVOR NWS5d3pGcW6mdXPld{BiKGS{YX3heIlkKGmwY4LlZZNmKG:oIFPSSWIyKGGldHn2bZR6 M4PtN|I2PTR6MEm5
ThGCs  M4rXU2Z2dmO2aX;uJGF{e2G7 M{HM[FEx6oDMzszN NW\WUYNjPOLCini= NY\HW|dw[XWpbXXueJMhUEmIMVGgcIV3\Wy|IIToZZQhf2W{ZTDzeIlufWyjdHXkJIJ6KEOxQ3yy MnzmNlU1OzNyMke=
ThGCs  MlrTSpVv[3Srb36gRZN{[Xl? MVOxNQKBks7:TR?= MoXhOQKBkmh? NFv3elJqdmO{ZXHz[ZMhS2:FbEKtbY5lfWOnZDDFSG4zyqCpZX7lJIV5eHKnc4Ppc44> NUjt[3ZvOjV2M{OwNlc>
ThGCs  NG\DeldHfW6ldHnvckBCe3OjeR?= MojqNVDjiIsQvF2= M32wcFMhcA>? M1fYUolvcGmkaYTzJJRp\SCnZn\lZ5Qhd2ZiSELPNkBwdiCHRF6yJI1TVkF? MV[yOVQ{OzB{Nx?=
RBMECs MY\GeY5kfGmxbjDBd5NigQ>? M2DRZVAvODVxMD61M|Uh|ryP M4TRTFAvOjViaB?= NWPve3o4cW6lcnXhd4V{KGODTWCgZ49v[2WwdILheIlwdg>? MWqyOVQyPjZ3MR?=
RBMECs MXXGeY5kfGmxbjDBd5NigQ>? Ml:yOeKh|ryP NIfWZ|kyKGh? MoD4Zoxw[2u|IITo[UBi[3SrdnH0bY9vKG:oIGLoc2EwWk:FSzDpcoR2[2WmIHL5JGVOSVBvSVm= M3HUT|I2PDF4NkWx
RBMECs MYLGeY5kfGmxbjDBd5NigQ>? NHTENYg2yqEQvF2= Mnf3NUBp Mmr6dJJmfmWwdIOgeIhmKEWPQWCtTWkucW6mdXPl[EBVTUWUII\hcJVmKGSnY4LlZZNm MV:yOVQyPjZ3MR?=
RBMECs Mkm1SpVv[3Srb36gRZN{[Xl? MX21xsDPxE1? MYqxJIg> MnPTdJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIFjSVEBndHW6IHHjdo9{eyC2aHWgRnRDKGmwZIXj[YQh[nliIFXNRXAuUUl? MXyyOVQyPjZ3MR?=
RBMECs M3fsVGZ2dmO2aX;uJGF{e2G7 MXK1xsDPxE1? NFP4ZW8yKGh? M4GycYlvcGmkaYTzJJRp\SCmZXPy[YF{\WRib3[gZY1wfW62IH;mJHpQNTFiaX6gUWZ{KGmwZIXj[YQh[nliRV3BVE1KUQ>? M2iyeVI2PDF4NkWx
RBMECs M4TuOmZ2dmO2aX;uJGF{e2G7 Mn7iOeKh|ryP NFfTcmIyKGh? MYDy[ZZmenOnczD0bIUh[2ijbnfld{BqdiCcTz2xJIRqe3S{aXL1eIlwdiC|ZXXuJJdqfGhiRV3BVE1KUSC2cnXheI1mdnR? NFPiUoszPTRzNk[1NS=>
RBMECs NV\r[ldCTnWwY4Tpc44hSXO|YYm= NFvRT482yqEQvF2= MYWxJIg> MWnicI9kc3NidHjlJGVOSVBvSVmtbY5lfWOnZDDjbIFv\2ViaX6gUWxEKHCqb4PwbI9zgWyjdHnvci=> NX;CPXFXOjV2MU[2OVE>
RBMECs NVn3N2xRTnWwY4Tpc44hSXO|YYm= M2jQdFXDqM7:TR?= M3vpNVEhcA>? M3XSVYJtd2OtczD0bIUh[WO2aX6gZ5l1d3OtZXzleI9vKHKnYYLyZY5o\W2nboSgd4VmdiC5aYToJGVOSVBvSVmgeJJm[XSvZX70xsA> M3T3SFI2PDF4NkWx
Primary bovine chondrocytes MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe1{txO M{LGdFQ5KGh? M4DHfJJmfmW{c3XzJJRp\SCrbnjpZol1d3K7IHXm[oVkfCCxZjDj[Yxm[2:6aXKgc44heHKxbHnm[ZJifGmxbjDpckBoem:5dHigdIxifGViY3jvcoRzd2O7dHXz NYSzWXp3OjV2ME[wNVY>
EM1  MnjZSpVv[3Srb36gRZN{[Xl? M{LFPFE26oDMzszN MlzVOFghcA>? MWTy[YR2[2W|IITo[UBmgHC{ZYPzbY9vKG:owrDMTWbDqG:{wrDQWGdUOsLiaX9CpGNCVFJvIH;yxsBGWEGFMj3zbYxmdmOnZDDFUVEh[2WubIRCpC=> MYmyOVM4QDZ4MR?=
BeWo  MmPHSpVv[3Srb36gRZN{[Xl? MXyyNOKhyrWP MVi0POKhcMLi MXvEUXNQyqB? M{\3NYlv[3KnYYPld{B1cGViYnX0ZU1pS0dicnXs[YF{\Q>? M2XVdVI2OzZ{Mk[w
BeWo  NXTXTGZXTnWwY4Tpc44hSXO|YYm= NUHpXHpzOjEEoNM1US=> M3HpNVQ5yqCqwrC= M1y0fGROW00EoB?= NF[4SoZld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBVVUWPRkG2 NX7MOZpOOjV|NkKyOlA>
BeWo  NGXXSYVHfW6ldHnvckBCe3OjeR?= MkPjNlDDqML3TR?= NV3YNFQ4PDkEoHlCpC=> MX\EUXNQyqB? MmrE[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gS2NONTF? MVSyOVM3OjJ4MB?=
granulosa cells MXHGeY5kfGmxbjDBd5NigQ>? MV2xNEDPxE1? MoGxNVIwOjRiaB?= NF\ld2tqdmO{ZXHz[ZMhfGinIHzleoVteyCxZtMgVmdUOsLibWLORS=> MnjJNlU{OzlzMEW=
granulosa cells NUnpbnZvTnWwY4Tpc44hSXO|YYm= NF\6[o0yOCEQvF2= NGD0dWMyOi9{NDDo Moe1bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicnXwc5J1\XJiYXP0bZZqfHliZn;yJJRp\SCub37n[ZN1KG[{YXft[Y51KCkkiKK4OVQwMzF6UlfTNk5NXUNr NUn1b3A1OjV|M{mxNFU>
granulosa cells M{\4T2Z2dmO2aX;uJGF{e2G7 NY\4TGd{OTBizszN NV\NSVVPOjRiaB?= Ml;ybY5kemWjc3XzJJRp\SCrboTlcpNqfHlib3[gSG5CN3C{b4TlbY4h[2:vcHzlfC=> M4PqdFI2OzN7MUC1
granulosa cells M2riPWZ2dmO2aX;uJGF{e2G7 NES0UIoyOCEQvF2= Ml:wNlQhcA>? NWDse5JucW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVmdUOiCycn;tc5RmeiCjY4Tpeol1gQ>? MkK3NlU{OzlzMEW=
SK-N-AS  NIjmS3BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGTnXlQyOCEQvF5CpC=> NVvYboJvOjRxNEigbC=> NEP4TYdmdmijbnPld{B1cW2nLXTldIVv\GWwdHz5JINmdGy3bHHyJJZq[WKrbHn0feKh MnflNlUzPjZyNkO=
SK-N-AS  NF3hTlZHfW6ldHnvckBCe3OjeR?= NVPGV2RsOTBizszNxsA> MXyyOEBp NG\j[mpqdmO{ZXHz[ZMhfGinIHPBUXAhdGW4ZXzzxsA> MnTMNlUzPjZyNkO=
SK-N-AS  NH61R3FHfW6ldHnvckBCe3OjeR?= NVyzOWhVOTBizszNxsA> MkPqNlQhcA>? MVzpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gZ5lkdGmwIFSx MWOyOVI3PjB4Mx?=
SK-N-AS  Mn7tSpVv[3Srb36gRZN{[Xl? M4\PWVExKM7:TdMg NWLwfXIzOzBibXnu NYrDWmpjcW6mdXPld{BxcG:|cHjvdplt[XSrb36gc4Yh|rJvY3H0[Y5qdiBqc3XyOlc2MSxicD3HV2s{|rJiKIPldlkqKGGwZDDjc45kd22rdHHueEBpcWeqZYKgcIV3\Wy|IH;mJIFkfGm4ZTygeY5xcG:|cHjvdplt[XSnZDyg{tIu[2G2ZX7pci=> NWPDRYlkOjV{Nk[wOlM>
SK-N-AS  MWTGeY5kfGmxbjDBd5NigQ>? NEXjS3kyOCEQvF5CpC=> NXqwPYFCOTBxM{CvOlAhdWmw NGDuO4NqdmO{ZXHz[ZMhdGW4ZXzzJI9nKHBvzsKtZ4F1\W6rbjCod4VzPjd3KTDhcoQhcW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gdE3Pui2lYYTlcolvKCi|ZYK2O|UqKGmwIDjw[ZJqMW63Y3zlZZIhemWpaX;udy=> MV:yOVI3PjB4Mx?=
SK-N-SH MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoHjNVAh|ryPwrC= NFnxN3o1QCCq MknX[Y5p[W6lZYOgV2suVi2VSDDu[ZVzd2KuYYP0c41iKGOnbHygeoli[mmuaYT5 NGXzUZkzPTJ4NkC2Ny=>
HEK‐CFTR NX[3fG1PTnWwY4Tpc44hSXO|YYm= M4T2OVLjiJN3MNMg{txO MkmwNE0yOiCvaX6= M33tO2ROW00EoB?= M3TP[olv\HWlZYOgZUBld3On4pEQ[IVx\W6mZX70JIlw\GmmZTDl[oZtfXkEoB?= NIK4PFQzPTJ4M{KwOy=>
L6 M{jlTGZ2dmO2aX;uJGF{e2G7 NYe1botsPDBiwsXN NYP0b2M{OjRiaB?= MorpbY5pcWKrdIOgSG1JOS2rbnT1Z4VlKEGtdDDhZ5RqfmG2aX;u MlvyNlUzPDd3NUC=
MIN6  MXfGeY5kfGmxbjDBd5NigQ>? NFXKXlMyOCEQvF5CpC=> NFmyXo4{KGh? MYTpcoNz\WG|ZYOgSFMhdVKQQTDlfJBz\XO|aX;u NI\ZWGszPTJ2MUGyOC=>
ventricular cardiomyocytes  MnLwSpVv[3Srb36gRZN{[Xl? NYjSfXMzOC5yMT2xNEDPxE1? MY\pcoNz\WG|ZYOgJINCVVBiYXPjeY12dGG2aX;u MUSyOVIxOzFzMx?=
ventricular cardiomyocytes  MnrvSpVv[3Srb36gRZN{[Xl? MkLENE4xOS1zMDFOwG0> MmD2[ZZwc2W|IHHuJIlvd3S{b4DpZ{Bz\XOyb37z[UAyOjEEsUG1KUBi[m:4ZTDiZZNidCC5aYToJIFvKEWFNUFCpI9nKDJwMjFCuW0> NU\zVZNLOjV{MEOxNVM>
BeWo  MYPGeY5kfGmxbjDBd5NigQ>? NX3DfGI4OjBiwsXN NXHsWGdWPDhiaB?= NVe3SIxuTE2VT9Mg MVTpcoR2[2W|IHPlcIwh\nW|aX;u MoPINlUyQDR2N{e=
THP-1  M3H5bmZ2dmO2aX;uJGF{e2G7 MmTqNU8yOCEQvF2= M{HvTFLDqGh? NHvRdHFFVVORwrC= NF7nUFV{fXCycnXzd4V{KE2FUD2xJJBzd2S3Y4Tpc47DqA>? NI\USZozPTF3NEi4Ni=>
Huh-7 MU\GeY5kfGmxbjDBd5NigQ>? NIXTPGsxNTJyIN88US=> MY[yJIjDqA>? Mlj3doV{fWy2czDpckBiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGNvTYnjJIV5eHKnc4Ppc44h[XRidHjlJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wy| M17wRlI2OTB7OEO0
C6 NHzR[nZHfW6ldHnvckBCe3OjeR?= M2jzUlExKM7:TdMg Mn[xNlAhdWmw NEnpc4ZqdmO{ZXHz[ZMh[0GPUDDhZ4N2dXWuYYTpc44> NX20U4FIOjVyNkm0NVc>
SW480 NVzaRWM3TnWwY4Tpc44hSXO|YYm= NGfZdIs1OMLizszN M4fkXVQ5yqCq NFzzWpVFVVOR MUPhZ5RqfmG2ZYOgVHAzSQ>? M2\NSlI1QTl5NEWx
HT-29  M2\h[mZ2dmO2aX;uJGF{e2G7 MlHnOFDDqM7:TR?= NHrrUng1QMLiaB?= MXLEUXNQ M{LPUYFkfGm4YYTld{BRWDKD MlLCNlQ6QTd2NUG=
SW480 MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ZOFDDqM7:TR?= MX:wMVczKGh? MofISG1UVw>? NGjGdpdqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 M4LHPFI1QTl5NEWx
HT-29  NEjDfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XiPVQxyqEQvF2= MYmwMVczKGh? M{LkXWROW09? MnXBbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> NYn1ZY5VOjR7OUe0OVE>
SW480 M1jHSGZ2dmO2aX;uJGF{e2G7 MU[0NOKh|ryP M4fPPFch\A>? NY\P[mJ1TE2VTx?= M3\iU5Jm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC= MkfuNlQ6QTd2NUG=
HT-29  MX3GeY5kfGmxbjDBd5NigQ>? MV60NOKh|ryP MXW3JIQ> MVXEUXNQ Mof3doVlfWOnczDjc4xwdm:|cHjldoUh\m:{bXH0bY9vKGOjcHHibYxqfHoEoB?= NWL0eJZYOjR7OUe0OVE>
SW480 NXG4d3JMSXCxcITvd4l{KEG|c3H5 MljGOFDDqM7:TR?= MYe0POKhcA>? MXLEUXNQ MnzzbY5lfWOnczDhckBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMz:3 NE\0N4QzPDl7N{S1NS=>
HT-29  M2L2PGFxd3C2b4Ppd{BCe3OjeR?= MUi0NOKh|ryP Ml7ZOFjDqGh? MYnEUXNQ M{\QZolv\HWlZYOgZY4h[WO2aY\heIlwdiCxZjDjZZNx[XOnIEOvOy=> M1W2cFI1QTl5NEWx
SW480 M3vXcmFxd3C2b4Ppd{BCe3OjeR?= NVPqV|hQPDEEoN88US=> NU\GSJBGPDkEoHi= NXPBVopGTE2VTx?= M3SxOYlv\HWlZYOgZ4hidmenczDpckB1cGVicHjvd5Bpd3K7bHH0bY9vKHO2YYT1d{Bw\iCSUELBJJRiemendIO= NEe5cIYzPDl7N{S1NS=>
HT-29  Mn\hRZBweHSxc3nzJGF{e2G7 NWLHeZVSPDEEoN88US=> NGTZeng1QMLiaB?= M3u3NWROW09? MWfpcoR2[2W|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS| NGHRbIczPDl7N{S1NS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

Protocol

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.5
Formula

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
Synonyms Coleonol

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

cAMP Signaling Pathway Map

Tags: buy Forskolin | Forskolin supplier | purchase Forskolin | Forskolin cost | Forskolin manufacturer | order Forskolin | Forskolin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID